0
Translating Basic Research Into Clinical Practice |

Therapeutic Potential of Mesenchymal Stem Cells for Severe Acute Lung Injury

Michael A. Matthay, MD; B. Taylor Thompson, MD; Elizabeth J. Read, MD; David H. McKenna, Jr, MD; Kathleen D. Liu, MD, PhD; Carolyn S. Calfee, MD; Jae Woo Lee, MD
Author and Funding Information

From the Departments of Medicine, Anesthesiology, and The Cardiovascular Research Institute at the University of California (Drs Matthay, Liu, Calfee, and Lee), San Francisco, CA; Blood Systems Research Institute (Dr Read), San Francisco, CA; Molecular and Cellular Therapeutics (Dr McKenna), University of Minnesota, Saint Paul, MN; and the Massachusetts General Hospital (Dr Thompson), Harvard Medical School, Boston, MA.

Correspondence to: Michael A. Matthay, MD, Departments of Medicine and Anesthesiology, 505 Parnassus Ave, M-917, San Francisco, CA 94143-0624; e-mail: michael.matthay@ucsf.edu


Funding/support: This study was supported by the National Heart, Blood, and Lung Institute (NHBLI) [NHBLI Grants R37 HL51856 and R01 HL51854] (Dr Matthay); [NHBLI Grant HL093026] (Dr Lee); [NHBLI Grants HL090833 and FAMRI] (Dr Calfee); [NHBLI Grant R37HL51856] (Dr Thompson); and [NHBLI Grant N01HB37164] (Dr McKenna).

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).


© 2010 American College of Chest Physicians


Chest. 2010;138(4):965-972. doi:10.1378/chest.10-0518
Text Size: A A A
Published online

Preclinical studies indicate that allogeneic human mesenchymal stem cells (MSC) may be useful for the treatment of several clinical disorders, including sepsis, acute renal failure, acute myocardial infarction, and more recently, acute lung injury (ALI). This article provides a brief review of the biologic qualities of MSC that make them suitable for the treatment of human diseases, as well as the experimental data that provide support for their potential efficacy for critically ill patients with acute respiratory failure from ALI. The article then discusses which patients with ALI might be the best candidates for cell-based therapy and provides a template for the regulatory and practical steps that will be required to test allogeneic human MSC in patients with severe ALI. There is a dual focus on how to design trials for testing both safety and efficacy.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543